ritlecitinib
Trade name: Litfulo
Small moleculeapproved
Approved
Jun 23, 2023
Clinical trial activity
51 trials · 6 clinical orgs · 1 marketing orgs
Phase 1
26
Phase 2
23
Phase 3
9
Phase 4
0
Earliest trial started Oct 1, 2011 (NCT01452373)
Timeline
2010s
Indications
Approved for
Studied for
- Adult · Phase 1
- Alopecia · Phase 2
- Alopecia Areata · Phase 3
- Arthritis, Rheumatoid · Phase 2
- Celiac Disease · Phase 2
- Chronic Urticaria · Phase 2
- Colitis, Ulcerative · Phase 2
- Crohn Disease · Phase 2
- Diabetes Mellitus, Type 1 · Phase 2
- Flushing · Phase 3
- Healthy Volunteers · Phase 1
- Hidradenitis Suppurativa · Phase 2
- Keloid · Phase 2
- Kidney Failure, Chronic · Phase 1
- Liver Diseases · Phase 1
- Lymphoma, T-Cell, Cutaneous · Phase 2
- Mycosis Fungoides · Phase 2
- Pharmacokinetics · Phase 1
- Sezary Syndrome · Phase 2
- Vasomotor System · Phase 3
- Vitiligo · Phase 3
Mechanism of action
- Tyrosine-protein kinase JAK3INHIBITOR
JAK3 inhibitor
- TEC family kinaseINHIBITOR
TEC family kinase inhibitor
- Estrogen receptorMODULATOR
Estrogen receptor modulator
SERM
Approval history
- approvedJun 23, 2023
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C- Mol. weight
- 285.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Black box warning
Sources
- ChEMBLCHEMBL68055 ↗
- ChEMBLCHEMBL5314649 ↗
- ChEMBLCHEMBL4085457 ↗
Also known as
- 1,1'-((1,3,6,8-tetrahydro-1,3,6,8-tetraoxobenzo(lmn)(3,8)phenanthroline-2,7-diyl)di-4,1-phenylene)bis(1-ethylpiperidinium),
- acolbifene
- acolbifene
- acolbifene
- acolbifene
- bis(4-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate
- bis(p-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate
- em 652
- em-652
- em-652
- em-652
- iem 652
- pf-06651600
- pf-06651600
- ritebronii
- ritebronium
- ritetronium
- ritetronium dibenzenesulfonate
- ritetroniy
- sch57068
- sch 57068
- sch-57068
- sch-57068
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07228390 | Phase 2 | Nov 13, 2025 | Pfizer |
| NCT07219615 | Phase 2 | Oct 30, 2025 | Pfizer |
| NCT07029828 | Phase 3 | Sep 10, 2025 | Pfizer |
| NCT07029711 | Phase 3 | Jul 31, 2025 | Pfizer |
| NCT06873945 | Phase 3 | Apr 1, 2025 | Pfizer |
| NCT06795373 | Phase 2 | Feb 28, 2025 | Icahn School of Medicine at Mount Sinai |
| NCT06373458 | Phase 2 | Aug 13, 2024 | Icahn School of Medicine at Mount Sinai, Pfizer |
| NCT06369454 | Phase 1 | May 3, 2024 | Pfizer |
| NCT06172348 | Phase 1 | Jan 2, 2024 | Pfizer |
| NCT06163326 | Phase 3 | Dec 22, 2023 | Pfizer |
| NCT06072183 | Phase 3 | Nov 8, 2023 | Pfizer |
| NCT05743244 | Phase 2 | Oct 19, 2023 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer |
| NCT05879458 | Phase 2 | May 17, 2023 | Icahn School of Medicine at Mount Sinai, Pfizer |
| NCT05852340 | Phase 1 | May 9, 2023 | Pfizer |
| NCT05650333 | Phase 1 | Jan 16, 2023 | Pfizer |
| NCT05636293 | Phase 2 | Jan 1, 2023 | Harvard University, Pfizer |
| NCT05583526 | Phase 3 | Dec 1, 2022 | Pfizer |
| NCT05549934 | Phase 2 | Sep 30, 2022 | Icahn School of Medicine at Mount Sinai, Pfizer |
| NCT05097716 | Phase 1 | Nov 2, 2021 | Pfizer |
| NCT05128058 | Phase 1 | Oct 22, 2021 | Pfizer |
Showing 20 of 51 trials
Page 1 / 3
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 49 | 44 | 4 | 2014 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 4 | 4 | 1 | 2022 |
| EndoCeutics Inc. | For profit | 1 | 1 | 1 | 2011 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Laval University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 1 | 1 | 2023 |
6 organizations
Page 1 / 1